CRISPR Therapeutics (CRSP)
(Delayed Data from NSDQ)
$46.41 USD
-1.81 (-3.75%)
Updated Aug 14, 2024 03:59 PM ET
After-Market: $46.50 +0.09 (0.19%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Brokerage Reports
CRISPR Therapeutics AG [CRSP]
Reports for Purchase
Showing records 201 - 220 ( 221 total )
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Healthcare - Key Takeaways From Our KOL Event Series at ASH 2019
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Healthcare - ASH 2019: Don''t Miss Our KOL Event Series at ASH!
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Don''t Need an Eraser to Edit. Key Takeaways from Our Call with Dr. Soni.
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Join The Call Today at 1 PM To Discuss Treatments for Hemoglobinopathies
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Healthcare - ASH 2019: Meet the Doctors Who Will Speak at Our KOL Event Series
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
ASH 2019: Keep Your Eyes Peeled For These Presentations!
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Gene-Editing Is Clearly Not A Fiction. Reiterate Buy. PT Raised To $100.
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
KOL Call with Dr. Sandeep Soni on December 4, 2019 at 1pm ET
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
3Q19 - Full Steam Ahead. Data Possible at ASH.
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
CRISPR Engineering Could Provide Immune-Evasive Cell Therapy for Diabetes
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
2Q19 Update - Raising Our PT to $65/ Share As CTX110 Enters The Clinic
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Momentum Builds With Two IND Approvals. Initiating at Buy. $50 PT.
Provider: Roth Capital Partners, Inc.
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.